Alterity Therapeutics Limited
PRNAF
$0.0101
$0.0065180.56%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | 7.90% | 4.55% | 0.07% | -21.27% | -36.59% |
| Total Revenue | 7.90% | 4.55% | 0.07% | -21.27% | -36.59% |
| Cost of Revenue | -19.28% | -22.87% | -26.69% | -30.48% | -33.27% |
| Gross Profit | 9.80% | 6.59% | 2.17% | -20.61% | -36.81% |
| SG&A Expenses | 39.52% | 14.81% | -7.86% | -14.55% | -20.24% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 666.00% | 72.95% | -82.74% | -77.42% | -71.43% |
| Total Operating Expenses | 47.73% | 36.20% | 24.25% | -3.62% | -26.65% |
| Operating Income | -58.32% | -44.65% | -30.72% | -1.61% | 23.46% |
| Income Before Tax | -59.65% | -48.15% | -35.86% | -8.50% | 16.59% |
| Income Tax Expenses | 7,500.00% | -12.14% | -56.63% | -83.77% | -99.67% |
| Earnings from Continuing Operations | -60.01% | -47.91% | -35.16% | -7.59% | 17.60% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -60.01% | -47.91% | -35.16% | -7.59% | 17.60% |
| EBIT | -58.32% | -44.65% | -30.72% | -1.61% | 23.46% |
| EBITDA | -58.52% | -44.79% | -30.82% | -1.61% | 23.53% |
| EPS Basic | 18.18% | 13.89% | 7.89% | 12.82% | 17.50% |
| Normalized Basic EPS | 20.00% | 18.18% | 16.67% | 20.00% | 23.08% |
| EPS Diluted | 15.15% | 13.89% | 7.89% | 12.82% | 19.51% |
| Normalized Diluted EPS | 20.00% | 18.18% | 16.67% | 20.00% | 23.08% |
| Average Basic Shares Outstanding | 104.33% | 77.56% | 50.29% | 26.56% | 2.65% |
| Average Diluted Shares Outstanding | 104.33% | 77.56% | 50.29% | 26.56% | 2.65% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
